Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BNTX 
BioNTech SE (BNTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: BNTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $137.02
1 Year Target Price $137.02
| 13 | Strong Buy |
| 3 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.48% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 24.80B USD | Price to earnings Ratio - | 1Y Target Price 137.02 |
Price to earnings Ratio - | 1Y Target Price 137.02 | ||
Volume (30-day avg) 21 | Beta 1.31 | 52 Weeks Range 81.20 - 129.27 | Updated Date 11/30/2025 |
52 Weeks Range 81.20 - 129.27 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-03 | When - | Estimate -1.02 | Actual -0.12 |
Profitability
Profit Margin -18.13% | Operating Margin (TTM) -2.17% |
Management Effectiveness
Return on Assets (TTM) -2.3% | Return on Equity (TTM) -3.04% |
Valuation
Trailing PE - | Forward PE 7.04 | Enterprise Value 8247355033 | Price to Sales(TTM) 7.87 |
Enterprise Value 8247355033 | Price to Sales(TTM) 7.87 | ||
Enterprise Value to Revenue 2.26 | Enterprise Value to EBITDA 41.61 | Shares Outstanding 240455450 | Shares Floating 93871403 |
Shares Outstanding 240455450 | Shares Floating 93871403 | ||
Percent Insiders 61.84 | Percent Institutions 22.51 |
Upturn AI SWOT
BioNTech SE
Company Overview
History and Background
BioNTech SE was founded in 2008 in Mainz, Germany, by Uu011fur u015eahin and u00d6zlem Tu00fcreci. Initially focused on developing individualized cancer immunotherapies, BioNTech gained global recognition for its rapid development of the first approved mRNA-based COVID-19 vaccine in partnership with Pfizer.
Core Business Areas
- mRNA-based Therapeutics: Development of mRNA-based vaccines and therapies for infectious diseases, cancer, and other diseases.
- Cell Therapies: Development of cell-based immunotherapies for cancer.
- Protein Therapeutics: Development of protein-based therapeutics for cancer.
Leadership and Structure
BioNTech is led by CEO Uu011fur u015eahin. The company has a supervisory board and a management board, responsible for overseeing and executing the company's strategy and operations.
Top Products and Market Share
Key Offerings
- Comirnaty (COVID-19 Vaccine): An mRNA-based vaccine developed in partnership with Pfizer. Significant revenue generated during the pandemic, but demand has since declined. Competitors include Moderna (MRNA), Novavax (NVAX), and Johnson & Johnson (JNJ).
- OncoRNA Platform: A platform developing mRNA-based cancer immunotherapies, which are currently in various stages of clinical trials. The potential addressable market for cancer therapies is substantial. Competitors vary depending on the specific cancer target.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high growth potential, rapid innovation, and intense competition. The mRNA technology platform is transforming vaccine development and therapeutic approaches across many diseases.
Positioning
BioNTech is a leading company in the mRNA technology space. Its successful development of a COVID-19 vaccine has established its credibility and enabled substantial investment in its pipeline. Competitive advantages include established technology, strong partnerships, and a large cash reserve.
Total Addressable Market (TAM)
The TAM for mRNA-based therapeutics and vaccines is estimated to be in the tens of billions of dollars and is growing rapidly, driven by advancements in technology and increasing investment. BioNTech is positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Proven mRNA technology platform
- Successful COVID-19 vaccine development
- Strong partnerships with Pfizer and other companies
- Robust cash reserves
- Experienced leadership team
Weaknesses
- Reliance on COVID-19 vaccine revenue
- Pipeline products in early stages of development
- Dependence on partner companies
- Limited commercial experience outside vaccines
Opportunities
- Expanding mRNA technology to new therapeutic areas
- Developing individualized cancer therapies
- Acquiring or partnering with other biotech companies
- Expanding into new geographic markets
- Developing vaccines for other infectious diseases
Threats
- Competition from other biotech and pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Patent disputes and intellectual property challenges
- Changes in government healthcare policies
- Decline in COVID-19 vaccine demand
Competitors and Market Share
Key Competitors
- MRNA
- LLY
- GILD
- VIR
Competitive Landscape
BioNTech's advantages include its validated mRNA technology and strong partnerships. Disadvantages include its reliance on COVID-19 vaccine revenue and the early stage of its pipeline products. Competitors have more diverse product portfolios and established commercial infrastructure.
Major Acquisitions
Kite Pharma cell therapy
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: Partnership to develop Kite Pharma cell therapy. No official acqisition recorded.
Growth Trajectory and Initiatives
Historical Growth: BioNTech experienced exponential growth during the COVID-19 pandemic due to the success of its vaccine. However, the company's future growth will depend on the success of its pipeline products.
Future Projections: Future growth projections require access to real-time analyst estimates and cannot be provided at this time.
Recent Initiatives: Recent strategic initiatives include acquisitions of other biotech companies, expansion of its research and development pipeline, and partnerships with pharmaceutical companies to develop and commercialize new therapies.
Summary
BioNTech is a leading biotechnology company with a validated mRNA platform and substantial resources. The company's future success depends on diversifying its revenue streams beyond the COVID-19 vaccine and successfully developing its pipeline products. Threats include competition and clinical trial risks. However, BioNTech's strong partnerships, experienced leadership, and robust cash position provide a solid foundation for future growth and innovation.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company reports
- Financial news outlets
- Industry analysis reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The data may not be entirely up-to-date and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioNTech SE
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-10-10 | Co-Founder, CEO & Chair of the Management Board Dr. Ugur Sahin M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6772 | Website https://www.biontech.de |
Full time employees 6772 | Website https://www.biontech.de | ||
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.